CN1532281A - Carcinoembryonic antigen gene fragment recombination and gene vaccine - Google Patents
Carcinoembryonic antigen gene fragment recombination and gene vaccine Download PDFInfo
- Publication number
- CN1532281A CN1532281A CNA031112528A CN03111252A CN1532281A CN 1532281 A CN1532281 A CN 1532281A CN A031112528 A CNA031112528 A CN A031112528A CN 03111252 A CN03111252 A CN 03111252A CN 1532281 A CN1532281 A CN 1532281A
- Authority
- CN
- China
- Prior art keywords
- cea
- gene
- vaccine
- carcinoembryonic antigen
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 39
- 229960005486 vaccine Drugs 0.000 title claims abstract description 30
- 239000012634 fragment Substances 0.000 title claims abstract description 25
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 title claims abstract description 12
- 238000005215 recombination Methods 0.000 title abstract description 8
- 230000006798 recombination Effects 0.000 title abstract description 6
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims abstract description 45
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims abstract description 37
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims abstract description 37
- 101150045267 CEA gene Proteins 0.000 claims abstract description 13
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 11
- 108091026890 Coding region Proteins 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 108020004414 DNA Proteins 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 12
- 108091008146 restriction endonucleases Proteins 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 7
- 102000003960 Ligases Human genes 0.000 claims description 4
- 108090000364 Ligases Proteins 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 3
- 108091061960 Naked DNA Proteins 0.000 claims description 3
- 108700026244 Open Reading Frames Proteins 0.000 claims description 3
- 238000003757 reverse transcription PCR Methods 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000000364 acidic sodium aluminium phosphate Substances 0.000 claims 1
- 239000001648 tannin Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 10
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 6
- 230000005847 immunogenicity Effects 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 230000005975 antitumor immune response Effects 0.000 abstract description 2
- 229940031348 multivalent vaccine Drugs 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000008521 reorganization Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010041986 DNA Vaccines Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229940022007 naked DNA vaccine Drugs 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- GLXHFRGBLGCWIK-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]tetradecanoic acid Chemical compound C(CCCCCCCCCCC)C(C(=O)O)N(C)C(N)=N GLXHFRGBLGCWIK-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
- 101000942941 Arabidopsis thaliana DNA ligase 6 Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A carcinoembryonic antigen gene fragment, a production method and a carcinoembryonic antigen gene vaccine, belonging to the technical field of biology. The invention aims to provide a section of 1.1Kb CEA gene fragment recombination and CEA gene vaccine which is prepared by using a gene recombination technology, does not comprise I, II functional regions of CEA genes, and only comprises CEA signal peptide coding regions and III region sequences. In the expression process of the CEA vaccine, the interference among the repeated sequences can be eliminated, the immunogenicity is enhanced, T cells are more effectively activated, and the specific anti-tumor immune response is induced. Meanwhile, because the newly prepared gene segment is shorter, the gene segment is easy to recombine with other immune enhancement genes and tumor genes to prepare combined or multivalent vaccines, and the anti-tumor effect of the gene vaccines is further improved.
Description
Technical field:
The present invention be a reorganization the CEA gene fragment and a kind of be the CEA naked DNA gene vaccine that foreign gene makes up with this fragment, belong to biological technical field.
Background technology:
(Carcinoembryonic antigen is by the tumour in human body entoderm source expressed important tumor associated antigen and generally acknowledged in the world tumor markers CEA) to carcinomebryonic antigen.The CEA positive tumor comprises 90% digestive tract cancer, 70% lung cancer and 50% mammary cancer etc., is in first of the malignant tumour M ﹠ M, and the serious threat mankind's life and health is badly in need of seeking a kind of effective ways of thorough radical cure clinically.
Tumor gene vaccine combines immunotherapy of tumors and gene therapy two aspect contents, is one of the most potential current oncotherapy means.
But in its development, should be noted that and solve following key issue: 1. screen and identify tumour antigen; 2. the immunogenicity of enhancement antigen; 3. effective activated T cell is removed immunosuppression; 4. improve the security of vaccine.At present in the world development be that the gene vaccine of target spot mainly contains vector-viral vaccine and naked DNA vaccine with CEA.Though virus vector can strengthen the immunogenicity of CEA, and the angtigen presentation effect is arranged; But naked DNA vaccine is because use eukaryon expression plasmid as carrier, with the genome conformity of host cell the time, inserts sudden change and possibility of infection, is more suitable in preparation human body vaccine than virus vector.But up to now, what use in the CEA naked DNA vaccine is the full cDNA sequence of CEA, and fragment is longer, and immunocompetence is not high.
Find according to result of study, in the structure of dna vaccination, remove the partial function encoding sequence, can strengthen the antigenicity of vaccine some viruses, bacterium, protozoon and tumour immunity.The about 3.1Kb of known CEAcDNA total length mainly is made of similar repeating unit (I, II, III district) on signal peptide encoding gene and three structures, encodes and contains 686 amino acid whose CEA molecules.By three sequential analyses that repeat function unit carries out are shown that wherein 70% aminoacid sequence is guarded, this disappearance that just means one or two repeating unit will can not influence the antigenicity of proteins encoded.
Technology contents:
The object of the present invention is to provide one section utilization gene recombination technology I, II functional zone preparation, that do not comprise the CEA gene, and only contain the reorganization of 1.1Kb CEA gene fragment and the CEA gene vaccine of CEA signal peptide coding region and III region sequence.
Carcinoembryonic antigen fragment of the present invention comprises the 1.1Kb CEA portion gene of CEA signal peptide and III district encoding sequence.
The nucleotide sequence and the open reading frame of 1091 bp CEA gene fragments
1 CAGAGGAATT?CAGAGCAGAC?AGCAGAGACC?
ATG?GAGTCTC?CCTCGGCCCC
TCCCCACAGA
[ORF]?M E S P S A P P H R
61?TGGTGCATCC?CCTGGCAGAG?GCTCCTGCTC?ACAGCCTCAC?TTCTAACCTT?CTGGAACCCG
W C I P W Q R L L L T A S L L T F
W N P
121?CCCACCACTG?CCAAGCTCAC?TATTGAATCC?ACGCCGTTCA?ATGTCGCAGA?GGGGAAGGAG
P T T A K L T I E S T P F N V A E
G K E
181?GTGCTTCTAC?TTGTCCACAA?TCTGCCCCAG?CATCTTTTTG?GCTACAGCTG?GTACAAAGGT
V L L L V H N L P Q H L F G Y S W
Y K G
241?GAAAGAGTGG?ATGGCAACCG?TCAAATTATA?GGATATGTAA?TAGGAACTCA?ACAAGCTACC
E R V D G N R Q I I G Y V I G T Q
Q A T
301?CCAGGGCCCG?CATACAGTGG?TCGAGAGATA?ATATACCCCA?ATGCATCCCT?GCTGATCCAG
P G P A Y S G R E I I Y P N A S L
L I Q
361?AACATCATCC?AGAATGACAC?AGGATTCTAC?ACCCTACACG?TCATAAAGTC?AGATCTTGTG
N I I Q N D T G F Y T L H V I K S
D L V
421?AATGAAGAAG?CAACTGGCCA?GTTCCGGGTA?TACTCGAGGC?TGCCCAAGCC?CTCCATCTCC
N E E A T G Q F R V Y S R L P K P
S I S
481?AGCAACAACT?CCAAACCCGT?GGAGGACAAG?GATGCTGTGG?CCTTCACCTG?TGAACCTGAG
S N N S K P V E D K D A V A F T C E
P E
541?GCTCAGAACA?CAACCTACCT?GTGGTGGGTA?AATGGTCAGA?GCCTCCCAGT?CAGTCCCAGG
A Q N T T Y L W W V N G Q S L P V S
P R
601?CTGCAGCTGT?CCAATGGCAA?CAGGACCCTC?ACTCTATTCA?ATGTCACAAG?AAATGACGCA
L Q L S N G N R T L T L F N V T R N
D A
661?AGAGCCTATG?TATGTGGAAT?CCAGAACTCA?GTGAGTGCAA?ACCGCAGTGA?CCCAGTCACC
R A Y V C G I Q N S V S A N R S D P
V T
721?CTGGATGTCC?TCTATGGGCC?GGACACCCCC?ATCATTTCCC?CCCCAGACTC?GTCTTACCTT
L D V L Y G P D T P I I S P P D S
S
Y L
781?TCGGGAGCGA?ACCTCAACCT?CTCCTGCCAC?TCGGCCTCTA?ACCCATCCCC?GCAGTATTCT
S G A N L N L S C H S A S N P S
P Q Y S
841?TGGCGTATCA?ATGGGATACC?GCAGCAACAC?ACACAAGTTC?TCTTTATCGC?CAAAATCACG
W R I N G I P Q Q H T Q V L F I A K
I T
901?CCAAATAATA?ACGGGACCTA?TGCCTGTTTT?GTCTCTAACT?TGGCTACTGG?CCGCAATAAT
P N N N G
T Y A C F V S N L A T G
R N N
961?TCCATAGTCA?AGAGCATCAC?AGTCTCTGCA?TCTGGAACTT?CTCCTGGTCT?CTGAGCTGGG
S I V K S I T V S A S G T S P G
L S A G
1021?GCGACTGTCG?GCATCATGAT?TGGAGTGCTG?GTTGGGGTTG?CTCTGATA?
TA?G?CAGCCCTGGG
A T V G I M I G V L V G V A L I
1081?TGTGGACCTT?C
The segmental production method of carcinoembryonic antigen is the restriction enzyme site (CTCGAG) that has added XhoI in 3 ' end PCR primer of 5 ' end of CEA signal peptide coding region and III region sequence, make two kinds of gene fragments that RT-PCR amplifies after restriction enzyme XhoI effect, has identical sticky end, and can be connected synthetic target gene fragment by dna ligase.
The carcinoembryonic antigen vaccine, the multiple clone site with CEA fragment insertion carrier for expression of eukaryon pIRES1neo makes up CEA naked DNA gene vaccine.The foreign gene that is cloned into eucaryon plasmid pIRES1neo is a CEA portion gene fragment.
The CEA vaccine can be got rid of the interference between tumor-necrosis factor glycoproteins in the expression process, enhancing immunity originality, and more effectively activated T cell induces specificity antineoplastic immunity and replys.Simultaneously,, therefore be easy to make associating or polyvalent vaccine, further improve the antitumous effect of gene vaccine with other immunostimulant gene and oncogene reorganization because freshly prepd gene fragment is shorter.
Embodiment:
At first, design and synthesize specific PCR primer (primer 1:5 ' the C AGAG of amplification CEA signal peptide coding region respectively according to the gene order of CEA
GAATTCAGAGCAGACAGCAGAGACCATGGA 3 ' contains EcoRI restriction enzyme site and initiator codon; Primer 2: 5 ' AGC
CTCGAGTATACCCGGAACTGGCCAGTTG 3 ' contains the XhoI restriction enzyme site) and the primer (primer 3:5 ' AGTCTC of amplification III sequence
CTCGAGGCTGCCCAAGCCCTCCATC 3 ' contains the XhoI restriction enzyme site; Primer 4:5 ' GAA
GGATCCACACCAGGGCTGCTATATCAGA 3 ' contains
BamHIRestriction enzyme site and terminator codon), be template to carry again, use the synthetic corresponding gene fragment of RT-PCR technology from total RNA of large bowel cancer tissue, with two PCR products respectively the XhoI enzyme cut, the sticky end that produces connects with dna ligase, and preparation is about the CEA recombination of 1.1Kb.Then, with EcoRI and BamHI respectively enzyme cut recombination and carrier for expression of eukaryon pIRES1neo, through the DNA ligation, make up the pIRES-CEA recombinant plasmid.This plasmid is the CEA naked DNA vaccine, and it not only can be expressed in mammalian cell, and has colibacillary replicon and ampicillin resistance gene, can massive duplication production in intestinal bacteria.
Characteristics of the present invention and positively effect are the two big key element-foreign genes that constitute gene vaccine and the optimum combination of expression vector:
1, the reorganization of foreign gene
What participate in the antitumor immunity of organism reaction mainly is the T cell, the T cell recognition be not whole C EA antigen molecule, but CTL antigen peptide epi-position wherein.Therefore, we produce the III district fragment of CEA CTL epi-position-YLSGANLNL and TYACFVSNL at preferred can the coding from CEAcDNA, be connected in after the CEA signal peptide coding region, be used for the preparation of CEA gene vaccine, to get rid of the interference between tumor-necrosis factor glycoproteins, improve antigenic submission, improve the immunogenicity of gene vaccine, and make the effect of vaccine more single-minded, accurately and safety.
2. the selection of carrier for expression of eukaryon
The expression vector that gene therapy is in the past used places foreign gene and screening-gene respectively under the control of different promoters, so the expression of the two do not have inevitable dependency, has only 5-30% to express goal gene in the positive colony that screening obtains.(internal ribosome entry site IRES), inserts the CEA portion gene and the screening-gene Neo of multiple clone site and the eukaryon expression plasmid pIRES1neo of this experimental selection contains internal ribosome entry site
rLay respectively at the upstream and downstream of IRES, be in together under the regulation and control of the main immediate early promoter of the human cytomegalic inclusion disease virus that can in eukaryotic cell, efficiently express/enhanser CMV, behind the transfection target cell, can transcribe and translate CEA albumen and neomycin phosphotransferase II from a mRNA, make transfection after the resistance clone that the G418 screening obtains all is the cell strain of high expression level CEA gene, improved working efficiency.What also contain two copies among the pIRES1neo is core with CpG, have immunostimulation dna sequence dna (the immunostimulatory DNA quence of (5 ' AACGTT 3 ') of palindrome, ISS), can guide immune response to tilt, and significantly strengthen the antigenic immunne response of external source genes encoding to TH1.
Genetic vaccine combines the advantage of three generations's vaccine, has the validity of attenuated live vaccine, the security of subunit vaccine and the accuracy of gene vaccine concurrently.It is the simulating nature course of infection in vivo, continues to produce recombinant antigen protein, stimulates body immune system, excites the ideal anti-tumor immune response; The quality of vaccine is easy to control and estimates simultaneously, and convenient the storage and transportation, is suitable for scale operation, is with a wide range of applications and the commercialization potentiality.The present invention is according to the therapeutic purpose CEA gene fragment of having recombinated, and the DNA and the aminoacid sequence of vaccine are clear, and antigenicity is stronger, and has reduced the interference between the sequence, makes the effect of genetic immunization more single-minded, accurately and safety.Prove that through sequential analysis the opening code-reading frame shelf structure of CEA gene fragment is correct in the recon, and is consistent with experimental design, can in eukaryotic cell, obtain correct the expression and shearing, and be discerned by specific T-cells to newly-built pIRES-CEA plasmid,
Implementation method of the present invention is as follows:
One, the reorganization of CEA gene fragment
1, the PCR design of primers is with synthetic: the two pairs of PCR primers all design voluntarily and are synthesized by dna synthesizer with terminal cessation method.Primer sequence is as follows.
CEA signal peptide coding region primer:
Primer 15 ' CAGAG
GAATTCAGAGCAGACAGCAGAGACCATGGA3 '
(containing EcoRI restriction enzyme site and initiator codon)
Primer 25 ' AGCCTCGAGTATACCCGGAACTGGCCAGTTG 3 '
(contain
XhoIRestriction enzyme site)
III district encoding sequence primer:
Primer 35 ' AGTCTCCTCGAGGCTGCCCAAGCCCTCCATC 3 '
(contain
XhoIRestriction enzyme site)
Primer 45 ' GAAGGATCCACACCAGGGCTGCTATATCAGA 3 '
(contain
BamHIRestriction enzyme site and terminator codon)
2, extract the total RNA of Colorectal Carcinoma:
(1) gets fresh Colorectal Carcinoma, the per 0.1 gram tissue in back that is cut into small pieces adds the sex change lysate (4.0M guanidine thiocyanate, 25mM Trisodium Citrate pH7.0,0.5% dodecyl creatine sodium, 0.72% beta-mercaptoethanol) of 1.2ml precooling, in homogenizer, pulverize lysing cell.
(2) add 2M acetate and receive (pH4.0) 0.12ml, mix.
(3) add phenol: chloroform: primary isoamyl alcohol (25: 24: 1) 1.2ml, after firmly mixing, put 15min on ice.
(4) 4 ℃, the centrifugal 20min of 12000rpm.
(5) carefully shift the upper strata water, add the equal-volume Virahol, more than-20 ℃ of precipitation 30min.
(6) 4 ℃, the centrifugal 20min of 12000rpm.
(7) discard supernatant, add the resuspended RNA throw out of sex change liquid 1ml again.
(8) add the equal-volume Virahol, more than-20 ℃ of precipitation 30min.
(9) 4 ℃, the centrifugal 20min of 12000rpm.
(10) abandon clean supernatant, centrifugal 2 times of 75% washing with alcohol of usefulness precooling.
(11) after precipitation is dried, with 50 μ lDEPC water dissolution.
(12) ultraviolet spectrophotometer quantitatively after ,-20 ℃ of preservations are standby.
3, cDNA is synthetic
In reaction system, add RNA template 1-2 μ g, oligo (dT) successively
121 μ l (100 μ g/ml), dNTP (each 10mmol/L) 2 μ l, RNA enzyme inhibitors 20U, AMV ThermoScript II 20U, 10 * AMV reaction buffer, 2 μ l, add DEPC water to 20 μ l, 42 ℃ of water-bath 30min, 95 ℃ of 5min.
4, pcr amplification and product reclaim:
Add Auele Specific Primer 1+2 (or 3+4) 4 μ l (20pmol), dNTP8 μ l, Tag (Ex) polysaccharase 2.5U, 10 * Tag enzyme reaction buffer solution, 10 μ l in the above-mentioned reaction system again, add distilled water to 100 μ l.The cyclic amplification program is: pre-95 ℃ of 5min of sex change, then 95 ℃ of 1min of sex change, 58 ℃ of 1min of renaturation, extend 72 ℃ of 1.5min, 72 ℃ of 10min are fully extended in totally 30 circulations.Agarose gel electrophoresis reclaims with the DNA purification kit after identifying the PCR product.
5, the digestion with restriction enzyme of DNA:
The endonuclease reaction of DNA all carries out according to this condition, and promptly every μ g dna fragmentation adds the restriction enzyme reaction damping fluid of 1/10 volume with 5U digestion with restriction enzyme (being XhoI) herein, adds distilled water 10 times to the enzyme volume again.Provide according to restriction enzyme supplier thermotonus 2-3 hour.
6, DNA ligation:
Reaction system comprises CEA signal peptide coding region (sticky end that 3 ' end has the XhoI enzyme to cut) and III district encoding sequence (sticky end that 5 ' end has the XhoI enzyme to cut) each 0.5 μ g, T
4Dna ligase 1 μ l, 10 * T
4Dna ligase damping fluid 2 μ l, add distilled water to 20 μ l.16 ℃, connect 12-16 hour.
Two, make up eukaryon expression plasmid pIRES-CEA
1, double digestion reaction:
The CEA recombination and the linear carrier pIRES1neo that prepare the toughness end with EcoRI and BamH I respectively.
2, the connection of dna fragmentation:
The volume ratio of CEA recombination and linear carrier pIRES1neo is 1 in the reaction system: 2-4.16 ℃, connect 12-16 hour.
Three, the mass production of recombinant plasmid pIRES-CEA
1, preparation competence intestinal bacteria (Calcium Chloride Method):
(1) scrape with the aseptic inoculation ring and get frozen intestinal bacteria bacterial classification in liquid nitrogen, streak inoculation is cultivated 12-16h for 37 ℃ in the LB agar plate.
(2) picking list bacterium colony is inoculated in the 5ml LB liquid nutrient medium, 37 ℃, 200rpm/min jolting cultivation 12h.
(3) get 1% nutrient solution, be inoculated in the 50ml LB liquid nutrient medium, 37 ℃, 250rpm/min jolting cultivation 2-3h are to OD
600=0.4-0.6.
(4) take out after ice bath 10min immediately.
Below all need aseptic technique.
(5) nutrient solution is transferred in the ice-cold 50ml centrifuge tube 4 ℃, the centrifugal 10min of 4000rpm.
(6) abandon clean supernatant liquor, ice-cold 0.1mol CaCl
2The resuspended thalline of 10ml, ice-water bath 30min.
(7) 4 ℃, the centrifugal 10min of 4000rpm abandon clean supernatant liquor.
(8) ice-cold 0.1mol CaCl
2The resuspended thalline of 2ml is placed 12-24h for 4 ℃, the competence bacterium.Can be packed as 200 μ l/ parts, add 30% glycerine ,-70 ℃ of preservations are standby.
2, bacterium transforms
(1) gets the 50ng plasmid and add and to contain in the aseptic glass test tube of 0.2ml competence bacterium, mixing gently, ice-water bath 30min.
(2) 42 ℃ of heat-shocked 90s.
(3) add 0.8 μ l LB liquid nutrient medium, 37 ℃, the gentle jolting 45mi of 120rpm/min.
(4) with glass elbow shop bacterium device 200 μ l bacterium liquid are applied in the agar culture dish that contains penbritin 50 μ g/ml, 37 ℃ keep flat absorption 20min after, be inverted and cultivate 10-14h.
3, the Rapid identification of recombinant plasmid
(1) will transform bacterium colony and transfer to successively in the agar culture dish that contains Amp, after the numbering, 37 ℃ of incubated overnight.
(2) an amount of bacterium colony of picking adds 25 μ l solution A, mixing.
(3) add 25 μ l solution B, mixing, behind 70 ℃ of insulation 5min, 4 ℃, the centrifugal 10min of 12000rpm.
(4) get supernatant, row agarose gel electrophoresis (comparing with empty plasmid simultaneously) determines whether to be recombinant plasmid according to the molecular weight size.
4, a large amount of extractions (alkaline lysis) of plasmid:
(1) 1% transformed bacteria is inoculated in the 100ml LB substratum (containing Amp50 μ g/ml), 37 ℃, 250rpm/min jolting cultivation 12-16h are to OD
600=0.6-0.8.
(2) take out after ice bath 10min immediately, transfer in the ice-cold 50ml centrifuge tube 4 ℃, the centrifugal 10min of 4000rpm.
(3) abandon clean supernatant liquor, add solution I (40mmol/L glucose, 2540mmol/L Tris-CI pH8.0, the 10mmol/L EDTA pH8.0) 4ml of ice precooling, the concuss mixing.
(4) add freshly prepared solution II (0.2mol/L NaCI, 1%SDS) 8ml, slowly put upside down mixing, place 5-10min.
(5) add ice-cold solution III (5mol/L potassium acetate 3.6ml, 3mol/L glacial acetic acid 0.69ml, distilled water 1.71ml) 6ml, put upside down mixing, ice-water bath 10min.4 ℃, the centrifugal 10min of 8000rpm.
(6) get supernatant liquor, add 0.6 volume primary isoamyl alcohol, mixing ,-20 ℃ of precipitation 20min.4 ℃, the centrifugal 10min of 12000rpm.
(7) abandon clean supernatant liquor, wash precipitation, dry, be dissolved in 1.2mlTE (pH8.0) solution with 70% ethanol.
(8) add Rnase A 30 μ l, 37 ℃ of water-bath 30min.
(9) add the equal-volume balance phenol, mix.The centrifugal 10min of 5000rpm.
(10) carefully draw the upper strata water, balance phenol extracting and chloroform-primary isoamyl alcohol (24: 1) extracting.
(11) the centrifugal 10min of 5000rpm carefully draws the upper strata water.
(12) add 1/10 volume NaAc (pH5.3), the dehydrated alcohol of 2.5 times of volumes, mixing ,-20 ℃ of precipitation 20min.
(13) the centrifugal 10min of 12000rpm abandons clean supernatant, and 70% washes 2 times.
(14) precipitation is dried, and is dissolved in 200 μ l TE (pH8.0) solution.
(15) get 10 μ l and measure OD by 1: 100 dilution back
260, calculate plasmid DNA concentration.-20 ℃ of preservations are standby.
Claims (4)
1, a kind of carcinoembryonic antigen fragment, it comprises the 1.1Kb CEA portion gene of CEA signal peptide and III district encoding sequence;
The nucleotide sequence and the open reading frame of 1091bp CEA gene fragment
1?CAGAGGAATT?CAGAGCAGAC?AGCAGAGACC?
ATG?GAGTCTCTCCCCACAGA
[ORF] M E S P S A P P H R
61 TGGTGCATCC?CCTGGCAGAG?GCTCCTGCTC?ACAGCCTCAC?TTCTAACCTT?CTGGAACCCG
W C I P W Q R L L L T A S L L T F
W N P
121 CCCACCACTG?CCAAGCTCAC?TATTGAATCC?ACGCCGTTCA?ATGTCGCAGA?GGGGAAGGAG
P T T A K L T I E S T P F N V A E
G K E
181 GTGCTTCTAC?TTGTCCACAA?TCTGCCCCAG?CATCTTTTTG?GCTACAGCTG?GTACAAAGGT
V L L L V H N L P Q H L F G Y S W
Y K G
241 GAAAGAGTGG?ATGGCAACCG?TCAAATTATA?GGATATGTAA?TAGGAACTCA?ACAAGCTACC
E R V D G N R Q I I G Y V I G T Q
Q A T
301 CCAGGGCCCG?CATACAGTGG?TCGAGAGATA?ATATACCCCA?ATGCATCCCT?GCTGATCCAG
P G P A Y S G R E I I Y P N A S L
L I Q
361 AACATCATCC?AGAATGACAC?AGGATTCTAC?ACCCTACACG?TCATAAAGTC?AGATCTTGTG
N I I Q N D T G F Y T L H V I K S
D L V
421 AATGAAGAAG?CAACTGGCCA?GTTCCGGGTA?TACTCGAGGC?TGCCCAAGCC?CTCCATCTCC
N E E A T G Q F R V Y S R L P K P
S I S
481 AGCAACAAGT?CCAAACCCGT?GGAGGACAAG?GATGCTGTGG?CCTTCACCTA?TGAACCTGAG
S N N S K P V E D K D A V A F T C E
P E
541 GCTCAGAACA?CAACCTACCT?GTGGTGGGTA?AATGGTCAGA?GCCTCCCAGT?CAGTCCCAGG
A Q N T T Y L W W V N G Q S L P V S
P R
601 CTGCAGCTGT?CCAATGGCAA?CAGGACCCTC?ACTCTATTCA?ATGTCACAAG?AAATGACGCA
L Q L S N G N R T L T L F N V T R N
D A
661 AGAGCCTATG?TATGTGGAAT?CCAGAACTCA?GTGAGTGCAA?ACCGCAGTGA?CCCAGTCACC
R A Y V C G I Q N S V S A N R S D P
V T
721 CTGGATGTCC?TCTATGGGCC?GGACACCCCC?ATCATTTCCC?CCCCAGACTC?GTCTTACCTT
L D V L Y G P D T P I I S P P D S
S
Y L
781 TCGGGAGCGA?ACCTCAACCT?CTCCTGCCAC?TCGGCCTCTA?ACCCATCCCC?GCAGATTCT
S G A N L N L S C H S A S N P S
P Q Y S
841 TGGCGTATCA?ATGGGATACC?GCACGAACAC?ACACAAGTTC?TCTTTATCGC?CAAAATCTCG
W R I N G I P Q Q H T Q V L F I A K
I T
901 CCAAATAATA?ACGGGACCTA?TGCCTGTTTT?GTCTCTAACT?TGGCTACTGG?CCGCAATAAT
P N N N G
T Y A C F V S N L A T G
R N N
961 TCCATAGTCA?AGAGCATCAC?AGTCTCTGCA?TCTGGAACTT?CTCCTGGTCT?CTCAGCTGGG
S I V K S I T V S A S G T S P G
L S A G
1021?GCCACTGTCG?GCATCATGAT?TGGAGTGCTG?GTTGGGGTTG?CTCTGATA?
TA?G?CAGCCCTGG
A T V G I M I G V L V G V A L I
1081?TGTGGACCTT?C
2, the segmental production method of carcinoembryonic antigen according to claim 1, it is characterized in that: hold the restriction enzyme site (CTCGAG) that has added Xho I in the PCR primer at 3 ' of 5 ' end of CEA signal peptide coding region and III region sequence, make two kinds of gene fragments that RT-PCR amplifies after restriction enzyme Xho I effect, has identical sticky end, and can be connected synthetic target gene fragment by dna ligase.
3, carcinoembryonic antigen vaccine according to claim 1 is characterized in that: the multiple clone site with CEA fragment insertion carrier for expression of eukaryon pIRES1neo makes up CEA naked DNA gene vaccine.
4, according to the described carcinoembryonic antigen vaccine of right claim 3, it is characterized in that: the foreign gene that is cloned into eucaryon plasmid pIRES1neo is a CEA portion gene fragment.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA031112528A CN1532281A (en) | 2003-03-21 | 2003-03-21 | Carcinoembryonic antigen gene fragment recombination and gene vaccine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA031112528A CN1532281A (en) | 2003-03-21 | 2003-03-21 | Carcinoembryonic antigen gene fragment recombination and gene vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1532281A true CN1532281A (en) | 2004-09-29 |
Family
ID=34283431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA031112528A Pending CN1532281A (en) | 2003-03-21 | 2003-03-21 | Carcinoembryonic antigen gene fragment recombination and gene vaccine |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1532281A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101928347A (en) * | 2010-05-05 | 2010-12-29 | 上海海抗中医药科技发展有限公司 | Anti-carcinoembryonic-antigen (CEA) antibody and application thereof |
EP3255055B1 (en) * | 2015-12-21 | 2024-06-05 | BrainOn Inc. | Composition for improving memory, learning ability and cognition |
-
2003
- 2003-03-21 CN CNA031112528A patent/CN1532281A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101928347A (en) * | 2010-05-05 | 2010-12-29 | 上海海抗中医药科技发展有限公司 | Anti-carcinoembryonic-antigen (CEA) antibody and application thereof |
CN101928347B (en) * | 2010-05-05 | 2013-03-27 | 上海海抗中医药科技发展有限公司 | Anti-carcinoembryonic-antigen (CEA) antibody and application thereof |
EP3255055B1 (en) * | 2015-12-21 | 2024-06-05 | BrainOn Inc. | Composition for improving memory, learning ability and cognition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1314916A (en) | Cancer antigens based on tumor suppressor gene WT1 product | |
CN101063104A (en) | Engineering bacterium producing 5-glycyl ethylformic acid and construction method thereof | |
CN1679930A (en) | Human papilloma virus and heat shock protein recombinant protein vaccine and use thereof | |
CN101063142A (en) | Human papilloma virus 16 type DNA vaccine and gene adjuvant and its application | |
CN1654656A (en) | FenneropenaeusChinensis Crustin gene and coded protein and cloning method therefor | |
CN1532281A (en) | Carcinoembryonic antigen gene fragment recombination and gene vaccine | |
TW202019947A (en) | Novel peptides and its derivatives capable of stimulating cytokine release | |
CN116359509A (en) | Tumor neoantigen screening method for gastric cancer treatment, preparation method and application of novel nano vaccine | |
CN1803846A (en) | Hybrid protein of p53 protein epitope(SQAMDDLMLS) and filobactivirus gene 8 protein and application thereof | |
CN1301749C (en) | Polyepitope DNA vaccine of anti-simple herpes virus-2 infection and its preparing method | |
CN1793373A (en) | Process for preparing human leucocyte interleukin 24 by genetic engineering and it expressing carrier and engineering bacterium | |
CN105176897A (en) | Recombinant engineering strain expressing GnRH/M2 fusion polypeptide and construction and application thereof | |
CN1255542C (en) | Constructing genetic engineering Vaccine of adhesin of confluent Helicobacter pylor and preparation method | |
CN1185254C (en) | First hypervariable region antigen of hepatitis C and fusion antigen | |
CN1552876A (en) | Targetted liver cancer AFP gene siRNAs expression carrier and its constructing method and use | |
CN1634982A (en) | Secretory expression of partial peptide segment of extracellular region of human carcinoembryonic antigen by eukaryotic cell | |
CN1403484A (en) | Prepn and application of transmembrane staphylococcus aureus toxin A fusion protein | |
CN103566378B (en) | Tumor nucleic acid vaccine based on tissue factor, preparation method and applications | |
CN1240714C (en) | Chirality peptide antigen and compon of bacterin based on core sequence of mucin 1 | |
CN1300321C (en) | Survivin mutant recombinant adenovirus with tumour cell death-promoting function and method for obtaining same | |
CN101525378B (en) | Listonella anguillarum subunit vaccine antigenic protein and application thereof | |
CN1141319C (en) | Method for efficiently expressing recombinant human interleukin 12 in eukaryotic cell | |
CN1635118A (en) | Synthesis of human carcinoembryonic antigen peptide epitope gene coded sequence concatemer and epitope vaccine | |
CN1313489C (en) | GP thymosin alpha 1 and preparation method | |
CN1284798C (en) | Poly thymosin-alpha 1, its composition, its preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |